RedHill Biopharma (RDHL) Cash from Investing Activities (2016 - 2021)
RedHill Biopharma has reported Cash from Investing Activities over the past 9 years, most recently at -$3.5 million for Q2 2021.
- Quarterly Cash from Investing Activities rose 92.97% to -$3.5 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was -$61.6 million through Jun 2021, up 19.69% year-over-year, with the annual reading at -$5000.0 for FY2025, 44.44% up from the prior year.
- Cash from Investing Activities was -$3.5 million for Q2 2021 at RedHill Biopharma, up from -$49.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$3.4 million in Q2 2019 and troughed at -$49.8 million in Q2 2020.
- The 4-year median for Cash from Investing Activities is -$4.9 million (2017), against an average of -$16.0 million.
- Year-over-year, Cash from Investing Activities crashed 1368.88% in 2020 and then surged 92.97% in 2021.
- A 4-year view of Cash from Investing Activities shows it stood at -$4.9 million in 2017, then skyrocketed by 30.4% to -$3.4 million in 2019, then crashed by 1368.88% to -$49.8 million in 2020, then surged by 92.97% to -$3.5 million in 2021.
- Per Business Quant, the three most recent readings for RDHL's Cash from Investing Activities are -$3.5 million (Q2 2021), -$49.8 million (Q2 2020), and -$3.4 million (Q2 2019).